0000899243-20-025451.txt : 20200916
0000899243-20-025451.hdr.sgml : 20200916
20200916205039
ACCESSION NUMBER: 0000899243-20-025451
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200916
FILED AS OF DATE: 20200916
DATE AS OF CHANGE: 20200916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 201179940
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-09-16
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
Series B Preferred Stock
Common Stock
1608785
D
The Series B Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Alternative Investments, as General Partner, By: /s/ Peter N. McIsaac, Title: Managing Director & Counsel
2020-09-16